Literature DB >> 26233590

Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy.

Peng Zhang1, Mian Xi1, Lei Zhao1, Bo Qiu1, Hui Liu1, Yong-Hong Hu1, Meng-Zhong Liu2.   

Abstract

BACKGROUND: Data on cervical esophageal cancer (CEC) based on modern radiotherapy technique are rare. We aimed to analyze the clinical efficacy and failure pattern of patients with CEC who underwent definitive chemoradiotherapy.
METHODS: Between February 2002 and October 2013, 102 patients with CEC treated with definitive chemoradiotherapy were retrospectively analyzed. All patients received concurrent platinum-based chemotherapy with conformal radiotherapy (50-70 Gy in 25-35 fractions, 5 fractions per week over 5-7 weeks). Overall survival (OS), progression-free survival (PFS) and loco-regional failure-free survival (LRFFS) were calculated.
RESULTS: The 3-year OS, PFS and LRFFS rates for the entire sample were 39.3%, 33.6% and 35.3%, respectively. During follow-up, 32, 26, and 41 patients had developed local, regional, and distant failure, respectively. Sex and hoarseness were independent prognostic indicators for OS (P=0.011, P<0.001; respectively) and PFS (P=0.008, P=0.001; respectively). Hoarseness was the only independent prognostic factor for LRFFS (P=0.002).
CONCLUSIONS: Distant metastasis was the most common failure pattern in CEC patients undergoing definitive chemoradiotherapy. Hoarseness was an independent prognostic factor for OS, PFS, and LRFFS.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cervical esophageal cancer; Chemoradiotherapy; Failure pattern; Prognosis; Prognostic factor

Mesh:

Year:  2015        PMID: 26233590     DOI: 10.1016/j.radonc.2015.07.011

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  22 in total

Review 1.  Cervical Esophageal Cancers: Challenges and Opportunities.

Authors:  Michael Buckstein; Jerry Liu
Journal:  Curr Oncol Rep       Date:  2019-04-04       Impact factor: 5.075

2.  Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.

Authors:  Hiroshi Okamoto; Yusuke Taniyama; Tadashi Sakurai; Takahiro Heishi; Jin Teshima; Chiaki Sato; Shota Maruyama; Ken Ito; Yu Onodera; Takuro Konno-Kumagai; Hirotaka Ishida; Takashi Kamei
Journal:  Esophagus       Date:  2018-06-15       Impact factor: 4.230

3.  Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.

Authors:  Matthias Felix Haefner; Kristin Lang; Vivek Verma; Stefan Alexander Koerber; Lorenz Uhlmann; Juergen Debus; Florian Sterzing
Journal:  Strahlenther Onkol       Date:  2017-09-15       Impact factor: 3.621

4.  Definitive chemoradiation for resectable carcinoma of the cervical esophagus: do we need more evidence?

Authors:  Antoine Adenis; Guillaume Piessen; David Azria
Journal:  Ann Transl Med       Date:  2017-12

Review 5.  Update on Management of Squamous Cell Esophageal Cancer.

Authors:  John K Waters; Scott I Reznik
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075

6.  Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis.

Authors:  Armando De Virgilio; Andrea Costantino; Carlo Castoro; Giuseppe Spriano; Bianca Maria Festa; Giuseppe Mercante; Davide Franceschini; Ciro Franzese; Marta Scorsetti; Andrea Marrari; Raffaele Cavina; Salvatore Marano
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-02       Impact factor: 4.553

7.  Regulator role of HPV E7 protein on miR-21 expression in cervical carcinoma cells and its functional implication.

Authors:  Qingqin Kong; Wenfeng Wang; Ping Li
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

8.  Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.

Authors:  Jie Li; Youling Gong; Peng Diao; Qingmei Huang; Yixue Wen; Binwei Lin; Hongwei Cai; Honggang Tian; Bing He; Lanlan Ji; Ping Guo; Jidong Miao; Xiaobo Du
Journal:  Radiat Oncol       Date:  2018-01-22       Impact factor: 3.481

9.  Combination of graphene oxide-silver nanoparticle nanocomposites and cisplatin enhances apoptosis and autophagy in human cervical cancer cells.

Authors:  Yu-Guo Yuan; Sangiliyandi Gurunathan
Journal:  Int J Nanomedicine       Date:  2017-09-05

10.  Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma.

Authors:  Katsuyuki Sakanaka; Yuichi Ishida; Kota Fujii; Satoshi Itasaka; Shin'ichi Miyamoto; Takahiro Horimatsu; Manabu Muto; Takashi Mizowaki
Journal:  Radiat Oncol       Date:  2018-01-18       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.